SIGN UPLog In

General

Financials

People

Activity

Recent News

Last deal

$25M

Amount

Post-IPO Debt

Stage

01.08.2023

Date

3

all rounds

$70.76M

Total amount

date founded

Financing round

General

About Company
Forte Biosciences is a clinical-stage biopharmaceutical company focused on developing treatments for cancer and inflammatory skin diseases.

Industry

Sector :

Subsector :

Keywords :

founded date

01.01.2017

Number of employees

51-100

Company Type

For Profit

Last funding type

Post-IPO Debt

IPO status

Private

Description

The company is pursuing the discovery, development, and commercialization of cancer treatments, with a focus on selective cancer immunotherapies. They are also developing a live biotherapeutic called FB-401 for the treatment of inflammatory skin diseases. FB-401 has completed Phase 1/2a testing and the company plans to advance it into a Phase 2 clinical trial.
Contacts

location

Sherman Oaks, Los Angeles, CA, USA

Contact Email

Phone number

Website URL

https://www.fortebiorx.com/home/default.aspx
Similar Companies
1000
89bio
89bio89bio is a biopharmaceutical company developing innovative therapies for liver diseases.
89bio

89bio

89bio is a biopharmaceutical company developing innovative therapies for liver diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Wellness, Health Care

Location

San Francisco, CA, USA

total rounds

7

total raised

$848.2M
Arcutis Biotherapeutics
Arcutis BiotherapeuticsArcutis Biotherapeutics is developing and commercializing treatments for immune-mediated dermatological diseases and conditions.
Arcutis Biotherapeutics

Arcutis Biotherapeutics

Arcutis Biotherapeutics is developing and commercializing treatments for immune-mediated dermatological diseases and conditions.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Westlake Village, CA, USA

total rounds

8

total raised

$833.5M
Aduro BioTech
Aduro BioTechAduro BioTech develops and sells therapies that use the body's immune system to treat diseases.
Aduro BioTech

Aduro BioTech

Aduro BioTech develops and sells therapies that use the body's immune system to treat diseases.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Biopharma

Location

Berkeley, CA, USA

total rounds

12

total raised

$359.66M
NemaGen Discoveries
NemaGen DiscoveriesNemaGen Discoveries advances therapies for allergic inflammation.
NemaGen Discoveries

NemaGen Discoveries

NemaGen Discoveries advances therapies for allergic inflammation.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Keywords

Biotechnology, Health Care, Therapeutics

Financials

Funding Rounds
3
3

Number of Funding Rounds

$70.76M

Money Raised

Their latest funding was raised on 01.08.2023. Their latest investor Alger. Their latest round Post-IPO Debt

Date 
Funding Round 
Investors 
Money Raised 
Lead 
01.08.2023
Post-IPO Debt
4
$25M
—
29.10.2020
Post-IPO Equity
—
$40M
—
27.11.2018
Venture - Series Unknown
—
$5.76M
—
Co-Investors
Investors
4
0

Number of lead investors

4

Number of investors

Investor 
Lead 
Round 
Partners 
Alger
Alger
No
Post-IPO Debt
—
Farallon Capital Management
Farallon Capital Management
No
Post-IPO Debt
—
Perceptive Advisors
Perceptive Advisors
No
Post-IPO Debt
—
Alger

Alger

Fred Alger Management is an investment advisor that manages client-focused equity portfolios and mutual funds.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Location

New York, NY, USA

count Of Investments

8

count Of Exists

1
Farallon Capital Management

Farallon Capital Management

Farallon Capital Management is an American capital management firm that invests globally across asset classes.

Sector

Investment Banking and Brokerage Services

Subsector

Asset Managers and Custodians

Keywords

Financial Services, Commercial Real Estate, Real Estate

Location

San Francisco, CA, USA

count Of Investments

67

count Of Exists

7
Perceptive Advisors

Perceptive Advisors

Perceptive Advisors is a privately owned hedge fund sponsor that finances global public equity markets.

Sector

Closed End Investments

Subsector

Closed End Investments

Keywords

Financial Services, Finance, Venture Capital

Location

New York, NY, USA

count Of Investments

256

count Of Exists

20
Acquisitions
1
Acquiree Name 
Date 
Price 
Acquisition Name 
Tocagen
Tocagen
20.02.2020
—
Forte Biosciences-Tocagen
Tocagen acquired by Forte Biosciences

Tocagen acquired by Forte Biosciences

acquirer

Forte Biosciences
Forte Biosciences

date

20.02.2020
Tocagen

Tocagen

Tocagen is a biopharmaceutical company developing gene therapy products for cancer treatment.

Sector

Pharmaceuticals and Biotechnology

Subsector

Biotechnology

Location

San Diego, CA, USA

total rounds

12

total raised

$198.61M

People

Employee Profiles
2
Eric Emery
Eric Emery

Eric Emery

Head of Downstream Manufacturing

Head of Downstream Manufacturing

Paul Wagner

Paul Wagner

Founder ,President & CEO

Founder ,President & CEO

Activity

Recent News
2
News Timeline

The graph reveals the ratio (%) of positive news articles in a chosen time range